Drug Development

© Enhanc3D Genomics

How Hazel Jones is charting new horizons in genomics

By Isabel Cameron

Hazel Jones is the CEO at Enhanc3D Genomics. We sat down with her to discuss her leap of faith into 3D genomics, and how she is scaling the business and driving operational change.

© Sharp

Breaking: Sharp acquires Berkshire Sterile Manufacturing

By Isabel Cameron

Sharp, a commercial pharma packaging and clinical trial supply services firm, has acquired Berkshire Sterile Manufacturing (BSM), a Massachusetts-based fill finish contract development and manufacturing organization (CDMO).

© Getty Images

Intellegens and CPI awarded £1.6m Innovate UK grant

By Isabel Cameron

Intellegens, a company applying machine learning (ML) to accelerate innovation in R&D, has secured a £1.6m grant from Innovate UK, to apply ML in the emerging field of oligonucleotide therapies.

© Getty Images

Adcendo raises $34 million to fund ADC treatments for sarcoma

By Jonathan Smith

The Danish biotech Adcendo has bagged a Series A extension round of €31 million ($33.8 million), taking its Series A winnings so far to €82 million ($89.5 million). The round will bankroll the development of Adcendo’s pipeline of antibody-drug...


NIH awards $577m to antiviral drug developers

By Rachel Arthur

The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, has awarded a total of $577m to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

(Image: Getty/wildpixel)

Immunai unveils map of human immune system

By Jenni Spinner

A research team including MIT, Harvard and Stanford researchers has raised $20m in seed funding for their effort to map out immune cells with machine learning.

(Image: Getty/Gajus)

Hired and Retired: Pharma C-suites see new faces

By Maggie Lynch

While last month saw many pharma executives leaving their positions to head towards smaller biotech companies, this month saw members of the industry climbing the ladder from various different starting points.